Expert Ratings For Beam Therapeutics
Expert Ratings For Beam Therapeutics
In the latest quarter, 5 analysts provided ratings for Beam Therapeutics (NASDAQ:BEAM), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.2, a high estimate of $57.00, and a low estimate of $35.00. This current average reflects an increase of 52.32% from the previous average price target of $30.33.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Beam Therapeutics among financial...
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧